Evidence Grade E — Very limited evidence. 2 published studies. 1 registered clinical trial.
Medically reviewed by a licensed medical professional
Testagen is a synthetic tetrapeptide from the Khavinson bioregulator programme. Despite its name (which suggests testosterone-related effects), the limited research focuses on the pituitary-thyroid axis, not testosterone. The name may create misleading expectations. No human clinical trials have been conducted and it has no regulatory approval.
Testagen is also known by these brand and alternate names:
2 published studies: 1 human, 0 animal, 1 in-vitro, 0 reviews
Testagen has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. An animal study using a hypophysectomised chicken model has been reported, along with in vitro cell penetration and histone interaction studies.
As with other Khavinson bioregulator peptides, the proposed mechanisms have not been independently validated. The compound's name may create misleading expectations about its proposed effects. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Testagen may penetrate cell nuclei and interact with specific DNA sequences. Cell penetration studies using fluorescence-labelled peptide in HeLa cells have been reported. Computational modelling suggests interactions with DNA regions. These observations are from in vitro and computational studies only.
Research consists almost entirely of work from the Khavinson group. The primary animal study uses a chicken model — not a mammalian model testing testosterone or testicular outcomes. No controlled human trials for testosterone or fertility endpoints exist. No pharmacokinetic data have been established. The disconnect between the compound's name and its actual research base is noteworthy. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 1 registered clinical trial for Testagen sourced from ClinicalTrials.gov.
Product Transference Study of Testagen™ TDS®-Testosterone
Testagen is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Gly (KEDG). Its molecular weight is 447.2 Da with the molecular formula C17H29N5O9 (CAS 1026993-38-3). Developed by Vladimir Khavinson as part of the cytomedine program, Testagen targets the pituitary-thyroid axis and hypothalamic-pituitary-gonadal axis. Not to be confused with Epitalon (AEDG, Ala-Glu-Asp-Gly) — Testagen substitutes lysine for alanine at position 1. No pharmacokinetic data exist.
Research suggests fluorescence-labeled KEDG penetrates cytoplasm, nucleus, and nucleolus of HeLa cells with the ability to discriminate between different nucleotide sequences and recognize cytosine methylation status. Computational modeling suggests affinity for DNA regions rich in CAAC nucleotides, potentially blocking DNA methyltransferase access. Research suggests KEDG also interacts with histones through unique spatial conformation. Proposed downstream effects include stimulation of Leydig cell activity, anterior pituitary stimulation (increased TSH), and promotion of stem cell differentiation.
A hypophysectomized chicken model (Kuznik et al. 2011) treated with KEDG showed apparent 23% increase in body weight, thyroid gland weight normalization, and morphological improvements. Nuclear penetration was confirmed by Fedoreyeva et al. (2011) using fluorescence-labeled KEDG in HeLa cells. Histone interactions were demonstrated by Fedoreyeva et al. (2013). Transport studies (Khavinson et al. 2023) showed effective binding to LAT1, LAT2, and PEPT1 transporters.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 5 vendor listings
View pricing data across vendors and countries for Testagen
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019. The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
Triptorelin is marketed as Trelstar (approved 2000) for advanced prostate cancer, available as intramuscular depot injections in monthly (3.75 mg), three-monthly (11.25 mg), and six-monthly (22.5 mg) formulations. It is also widely used internationally for gender-affirming care and central precocious puberty. Triptorelin is one of the most commonly used GnRH agonists globally, though it faces the same competitive pressure as other agents in this class from newer oral GnRH antagonists like relugolix, which avoid the initial hormone flare and offer potential cardiovascular advantages. Clinical data demonstrate reliable testosterone suppression comparable to other GnRH agonists in this class.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
